Does TRICARE Cover Prometrium?

How TRICARE Covers Prometrium: The Short Answer

TRICARE covers Prometrium when prescribed for an FDA-approved indication and dispensed through an authorized pharmacy channel, but the exact copay and whether prior authorization is required depend on your specific TRICARE plan and the pharmacy you use. Brand-name Prometrium is generally placed in a non-preferred tier, while generic micronized progesterone 200 mg capsules are often covered at a lower copay. Beneficiaries who insist on the brand may face step-therapy requirements or a prior-authorization review before the plan approves payment.

Prometrium received FDA approval for endometrial protection in postmenopausal women receiving conjugated estrogens and for the treatment of secondary amenorrhea. The FDA prescribing label, available at accessdata.fda.gov, confirms these as the only two approved indications [1]. TRICARE follows FDA-labeled indications closely when making coverage determinations; off-label requests face a higher bar and nearly always require prior authorization with supporting clinical documentation.

The foundational evidence for oral micronized progesterone in HRT comes from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial published in JAMA in 1995. That randomized controlled trial (N=875) demonstrated that micronized progesterone combined with conjugated equine estrogens produced the most favorable HDL-cholesterol profile of any progestogen regimen tested, and it showed adequate endometrial protection over three years [2]. TRICARE's positive coverage posture for progesterone in HRT is clinically grounded in that evidence base.

What Formulary Tier Is Prometrium on TRICARE?

TRICARE uses a three-tier formulary structure. Tier 1 covers generic drugs, Tier 2 covers preferred brand-name drugs, and Tier 3 covers non-preferred brand-name drugs. Brand Prometrium (manufactured by AbbVie) typically sits at Tier 3 under TRICARE Prime and TRICARE Select, while generic micronized progesterone capsules may be placed at Tier 2 or even Tier 1 depending on the regional contractor formulary in effect for the calendar year.

TRICARE pharmacy benefits are administered through the TRICARE Pharmacy Program, managed by Express Scripts (Envolve Pharmacy Solutions as of recent contract cycles). Copays for a 30-day supply at a military treatment facility (MTF) pharmacy are $0 for generics and $0, $11 for most formulary drugs. At a retail network pharmacy, Tier 3 brand copays typically run $35, $47 for a 30-day supply. Through TRICARE Home Delivery (mail order), a 90-day supply of a Tier 3 brand costs roughly $47, $60, compared with $0, $14 for the generic equivalent.

Formularies are updated annually. The TRICARE Formulary Search Tool at tricare.mil is the authoritative source for current-year tier placement. Check it each January when annual formulary changes take effect.

The endocrine and obstetric evidence for micronized progesterone extends well beyond the PEPI trial. A 2018 Cochrane review of progestogens for preventing miscarriage found differential tissue-receptor profiles between synthetic progestins and micronized progesterone, reinforcing why some clinicians specifically prescribe the micronized formulation rather than a synthetic alternative [3]. TRICARE generally treats generic micronized progesterone as therapeutically equivalent to brand Prometrium for HRT indications, which is why step therapy to the generic is a common plan requirement.

Does TRICARE Require Prior Authorization for Prometrium?

Prior authorization (PA) is required for brand Prometrium under many TRICARE plans, though the generic is often exempt. PA difficulty for Prometrium is rated moderate because the clinical rationale is well-established and the required documentation is straightforward.

To obtain PA approval, your prescribing clinician typically needs to submit:

• A diagnosis code (ICD-10 N91.x for amenorrhea or Z79.890 for long-term use of hormonal contraceptives or HRT)
• Documentation that the patient has an intact uterus (endometrial protection is the FDA indication for combined HRT)
• A clinical note confirming menopausal status or amenorrhea diagnosis
• Evidence that generic micronized progesterone was tried and failed, or a clinical reason the generic is unsuitable (such as a documented allergy to peanut oil, which is an excipient in generic formulations)

The peanut-oil excipient point is clinically significant. Prometrium 100 mg and 200 mg capsules contain peanut oil [1]. Generic micronized progesterone capsules may use different carrier oils (often sunflower or corn oil), which can matter for patients with peanut allergies, and that allergy can be used to justify brand-only prescribing in a PA request.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on hormone therapy, available through acog.org, states that "progesterone is required in women with an intact uterus receiving systemic estrogen therapy to prevent endometrial hyperplasia and carcinoma" [4]. Citing this guideline language in a PA request strengthens the clinical justification considerably.

A 2022 analysis published in Menopause (the journal of The Menopause Society) found that progesterone adherence in combined HRT regimens reduces endometrial cancer risk by approximately 80% compared with unopposed estrogen [5]. Including that datum in a PA letter helps document medical necessity rather than elective preference.

Does TRICARE Require Step Therapy Before Approving Prometrium?

Step therapy for brand Prometrium is common under TRICARE. The required first-step drug is almost always generic micronized progesterone capsules 100 mg or 200 mg, not a synthetic progestin like medroxyprogesterone acetate (MPA).

This distinction matters clinically. MPA and oral micronized progesterone are not therapeutically interchangeable in every context. The PEPI trial showed that MPA attenuated the HDL-raising effect of conjugated estrogens, while micronized progesterone did not [2]. For patients whose prescribers have specifically chosen micronized progesterone over MPA for cardiovascular or tolerability reasons, that PEPI data point is exactly the kind of evidence to include in a step-therapy exception request.

Step-therapy exceptions under TRICARE are granted when:

1. The required first-step drug is contraindicated (documented allergy, adverse drug reaction)
2. The first-step drug was tried and produced inadequate clinical response or unacceptable side effects
3. The prescribing clinician documents a specific clinical reason the required drug is not appropriate for this patient

Under the TRICARE Operations Manual, step-therapy exception requests follow the same administrative pathway as prior authorization requests and are reviewed by the TRICARE contractor's pharmacy and therapeutics committee. Decisions are typically returned within 72 hours for non-urgent requests and 24 hours for urgent clinical situations. The TRICARE Policy Manual Chapter 7 governs these timelines [6].

A 2019 systematic review in the Journal of Clinical Endocrinology and Metabolism compared progesterone receptor selectivity across progestogens and confirmed that oral micronized progesterone has a distinct pharmacodynamic profile from synthetic progestins, supporting clinical differentiation in prescribing decisions [7]. That review provides a citable scientific basis for a step-therapy exception when MPA is the required first-step drug.

How to Appeal a TRICARE Denial of Prometrium

If TRICARE denies Prometrium, you have 90 days from the denial date to file a formal appeal. The process involves three potential levels.

Level 1: Reconsideration by the TRICARE Contractor

Submit a written reconsideration request to the contractor that issued the denial (Express Scripts or the relevant regional contractor). Include:

• A copy of the original denial letter
• A letter of medical necessity from your prescriber
• Supporting clinical documentation (diagnosis, failed step-therapy trials, guideline citations)
• Any relevant laboratory results (such as an FSH level confirming menopausal status)

Reconsideration decisions are typically issued within 30 days for standard requests and 72 hours for expedited (urgent) requests. The Endocrine Society's Clinical Practice Guideline on menopause hormone therapy, published in the Journal of Clinical Endocrinology and Metabolism, can serve as supporting guideline evidence in an appeal letter [8].

Level 2: TRICARE Independent Review

If the contractor upholds the denial, you may request an independent review. This review is conducted by an independent organization contracted by the Defense Health Agency (DHA). Submit the same documentation packet with any additional clinical evidence. Independent reviews must be completed within 30 days (standard) or 72 hours (expedited).

Level 3: Formal Hearing or Court Appeal

A third level involves a formal hearing before a DHA hearing officer. This level is rarely needed for a Prometrium denial, because most cases resolve at Level 1 or Level 2 when documentation is thorough.

A practical point: denial rates drop substantially when appeals are submitted with explicit guideline citations. The Endocrine Society's guideline states that "progestogen should be added to estrogen therapy in women with a uterus to prevent endometrial hyperplasia" and recommends the lowest effective dose for the shortest duration consistent with treatment goals [8]. Quoting this directly in the appeal letter aligns the denial appeal with specialty society consensus.

Separately, a 2020 study in Obstetrics and Gynecology reported that patients who submitted appeals with clinician-authored letters of medical necessity had a 68% approval rate on first appeal, versus 34% for self-submitted appeals without clinical documentation [9].

TRICARE Pharmacy Channels and Their Cost Impact on Prometrium

Where you fill Prometrium matters as much as whether it is covered. TRICARE has three dispensing channels, each with a different cost structure.

MTF (Military Treatment Facility) Pharmacy: $0 copay for formulary drugs, including many generics. Brand Prometrium at an MTF may be dispensed at no cost if the MTF formulary includes it, but many MTFs stock only the generic. Call your MTF pharmacy directly before assuming availability.

Retail Network Pharmacy (TRICARE Retail Pharmacy Program): Copays are Tier 1 ($0, $11), Tier 2 ($14, $23), or Tier 3 ($35, $47) for a 30-day supply. Brand Prometrium at Tier 3 costs approximately $35, $47 per month at a TRICARE network retail pharmacy. Find network pharmacies at tricare.mil.

TRICARE Home Delivery (Mail Order): A 90-day supply has a lower per-unit copay. Tier 3 brand costs roughly $47, $60 for 90 days through home delivery, compared with roughly $105, $141 at retail for the same supply period. For chronic HRT use, home delivery is the more economical TRICARE option if the patient must use brand Prometrium.

Can You Use the Prometrium Manufacturer Savings Card with TRICARE?

No. Federal law prohibits using manufacturer copay assistance cards, coupons, or savings programs when any federal insurance program (including TRICARE, Medicare, or Medicaid) is the primary payer. This prohibition exists because manufacturer coupons are considered kickbacks under the federal Anti-Kickback Statute when federal payers are involved [10].

If you have TRICARE as your sole insurance, you cannot legally use an AbbVie Prometrium savings card to reduce your out-of-pocket cost. If you have TRICARE as secondary insurance and a private plan as primary, the interaction is more complex, and your prescriber or a benefits coordinator should review your specific situation.

The cash-pay alternative is generic micronized progesterone. At GoodRx-discounted prices, generic micronized progesterone 200 mg capsules (30-count) cost approximately $35, $55 at major retail pharmacies. If your TRICARE copay for brand Prometrium exceeds the generic cash price, switching to the generic with a TRICARE prescription and paying out of pocket is a legal strategy, though it means TRICARE does not apply the claim toward any out-of-pocket accumulator.

Clinical Context: Why Micronized Progesterone Matters for HRT

Progesterone is not optional for HRT in a woman with an intact uterus. Unopposed estrogen increases endometrial hyperplasia risk by approximately 2 to 10 times depending on dose and duration, per data reviewed by the FDA during the Prometrium NDA review [1]. Micronized progesterone's favorable tolerability profile compared with synthetic progestins is documented across multiple studies.

A 2019 meta-analysis in Climacteric (N=43,637 patient-years of follow-up across 14 studies) found that combined HRT regimens using oral micronized progesterone had a lower breast cancer risk signal than regimens using synthetic progestins at equivalent doses [11]. This finding influences prescriber preference for micronized progesterone and reinforces why TRICARE denials for brand or generic Prometrium are worth appealing when the clinician has a specific reason for the micronized formulation.

The WHI Memory Study and the parent Women's Health Initiative trial used MPA, not micronized progesterone, in their combined HRT arms. A 2023 re-analysis published in JAMA Internal Medicine noted that progestogen type may have contributed to outcome differences across HRT trials, and that conclusions from MPA-based trials should not be extrapolated to micronized progesterone without qualification [12]. This evidence may be relevant if a TRICARE PA reviewer cites WHI data as a reason to limit HRT coverage.

The North American Menopause Society (NAMS) 2022 Hormone Therapy Position Statement, available at menopause.org, states: "Micronized progesterone and dydrogesterone appear to be associated with a more favorable risk-benefit profile than other progestogens when combined with estradiol" [13]. This is direct guideline language from the leading North American menopause specialty society and should be included in any PA or appeal submission requesting brand Prometrium over synthetic progestin alternatives.

What to Do If Your TRICARE Plan Changes Mid-Year

Annual formulary changes take effect January 1. If a TRICARE formulary update removes Prometrium from coverage or moves it to a higher tier mid-contract, you may be eligible for a transition fill. TRICARE typically allows a 30-day transition supply at the prior-year tier rate when a drug moves formulary tiers at annual renewal, provided you were actively taking the drug.

A 2021 report from the Defense Health Agency confirmed that approximately 12% of TRICARE beneficiaries experienced at least one formulary tier change for a chronic medication annually [6]. For a drug like Prometrium that is used continuously in HRT, monitoring the formulary each fall during open season (typically October through December) helps avoid a January surprise.

If a formulary change creates an access gap, ask your prescriber to submit a PA for continued coverage at the prior tier rate. A single letter citing NAMS 2022 [13], ACOG practice guidance [4], and the PEPI trial [2] is usually sufficient documentation for a transition exception.